Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

GlobalData predicts that Lilly’s retatrutide could reach sales of $15.6bn in 2031. Image credit: Jennie Book / Shutterstock.com. Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight ...

FL is the most common indolent form of B-cell NHL. Credit: Motortion Films/Shutterstock.com. At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December, results from the global, ...

This marks the second delay for tolebrutinib in 2025 – Sanofi had originally anticipated a decision on the Bruton’s tyrosine kinase (BTK) inhibitor by the end of September. Credit: LCV via ...

In earlier Phase I/II data, microdystrophin concentration ranged from 20% to 122% after the pivotal dose. Credit: Sai Thaw Kyar / Shutterstock.com. REGENXBIO has concluded enrolment of subjects in the ...

Anova Enterprises has launched the AnovaOS SaaS platform, a new AI-based patient matching solution for clinical trials.

The trial will enrol 300 chronic low back pain patients with inflammatory degenerative disc disease of less than five years duration. Credit: Anatoliy Cherkas / Shutterstock. Australia-based Mesoblast ...

Almost three decades ago, the FDA allowed women back into clinical research to participate as subjects, but the representation of females remains an issue, especially in Phase I trials. A recent study ...

AI technology in clinical trials has the potential to speed up cohort selection and patient recruitment. However, data management and inherit bias in datasets need to be addressed first.

There have been several impactful clinical trial read outs in 2024. Image credit: Shutterstock / Rajitha Tennakoon From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure ...

Here are some trials for obesity medications to watch over the next 12 months. Image credit: Zdenek Macat / Getty Images The approval of Novo Nordisk’s Wegovy in 2021 catapulted the landscape of ...

The clinical trial sector reflects on what it believes will be the biggest difficulties of 2025. Image credit: Shutterstock / 3rdtimeluckystudio It has been a turbulent time for the pharmaceutical ...